Scopus BioPharma Inc.
SCPS
$0.0003
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.08M | 5.81M | 9.03M | 14.33M | 16.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.34M | 9.73M | 11.71M | 16.40M | 17.26M |
| Operating Income | -9.34M | -9.73M | -11.71M | -16.40M | -17.26M |
| Income Before Tax | -9.34M | -9.73M | -11.71M | -16.40M | -15.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.34 | -9.73 | -11.71 | -16.40 | -15.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 647.20K | 334.90K | 105.10K | -- | -- |
| Net Income | -8.70M | -9.40M | -11.61M | -16.40M | -15.90M |
| EBIT | -9.34M | -9.73M | -11.71M | -16.40M | -17.26M |
| EBITDA | -9.34M | -9.73M | -11.71M | -16.40M | -17.26M |
| EPS Basic | -0.32 | -0.41 | -0.55 | -0.81 | -0.80 |
| Normalized Basic EPS | -0.19 | -0.25 | -0.34 | -0.50 | -0.50 |
| EPS Diluted | -0.32 | -0.41 | -0.55 | -0.81 | -0.80 |
| Normalized Diluted EPS | -0.19 | -0.25 | -0.34 | -0.50 | -0.50 |
| Average Basic Shares Outstanding | 112.30M | 93.65M | 84.38M | 82.64M | 78.69M |
| Average Diluted Shares Outstanding | 112.30M | 93.65M | 84.38M | 82.64M | 78.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |